ReviewBiomarkers in medicine2025
Potentialities and challenges of liquid biopsy in clinical cancer management.
Review in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual-biomarkers encoding tumor-activatable minicircles with scaffold/matrix attachment region motif for sensitive and sustained blood and urine-based cancer detection.Cancer cell international · 2026Article
- Advances in Liquid Biopsy for Precision Oncology: Applications, Challenges, and Future Directions in Clinical Laboratories.OncoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of biomarkers through liquid biopsy, accompanied by low invasiveness, provides a more comprehensive analysis of the genetic profile of tumors, a deeper understanding of cancer mechanisms, the capacity for repeated testing over time, a short processing time, ease of obtaining, and economic benefits, making it easier to monitor diseases compared to tissue biopsy. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, non-coding RNAs, and metabolites provide precise and timely strategies for managing cancer patients. The main challenges are the low concentration of analytes isolated from liquid biopsies, the development of assays with both high sensitivity and specificity, and the lack of clear and comprehensive guidelines for assays, which further complicate the standardization process. Combined detection, including both CTCs and ctDNA assessment in circular bodies, provides valuable information at different stages of the tumor, despite the heterogeneity of tumor cells, for prognosis, dynamic monitoring, and mutation detection. In addition, the combination of biofluid biomarkers and artificial intelligence can enhance the accuracy and efficiency of liquid biopsy, improve real-time monitoring of tumor procedures and treatment responses, and provide precision medicine. This review examines the challenges in standardizing biofluid assays and explores potential solutions to achieve more consistent clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.